ANT-301 / Anterogen - LARVOL DELTA

ANT-301-102: Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Anterogen Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jun 2025 ➔ May 2026

Enrollment closed • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

ANT-301-102: Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients with Knee Osteoarthritis in Grade III/IV by K/L (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Anterogen Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2025 ➔ Jul 2026

Enrollment open • Trial completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Anterogen Co., Ltd.

New P1 trial • Immunology • Osteoarthritis • Pain • Rheumatology